论文部分内容阅读
目的观察前列地尔联合替米沙坦治疗慢性肾小球肾炎蛋白尿的临床效果。方法选取2012年8月-2013年12月该院收治的慢性肾小球肾炎蛋白尿确诊患者86例,随机分为治疗组和对照组各43例,对照组患者在入院时均给予常规治疗,如限盐、控制食物蛋白摄入、利尿等基础治疗;治疗组在上述对照组基础治疗上给予前列地尔10μg静脉推注,每天1次+替米沙坦80mg口服,每天1次,14d为1个疗程。治疗14d后观察比较2组治疗前后血肌酐(Scr)、24h尿蛋白定量(24h Upro)及血尿素氮(BUN)改善情况,及2组临床效果情况。结果 2组治疗14d后Scr、24h Upro、BUN与治疗前比较均明显下降,且治疗组治疗后较对照组治疗后下降更明显(P<0.05);治疗28d后治疗组总有效率为95.35%明显高于对照组的72.09%,差异均有统计学意义(P<0.05)。结论前列地尔与替米沙坦两药联合应用治疗慢性肾小球肾炎蛋白尿的临床效果显著,不良反应少,值得临床推广应用。
Objective To observe the clinical effect of alprostadil combined with Telmisartan in the treatment of chronic glomerulonephritis proteinuria. Methods Eighty-six patients with proteinuria of chronic glomerulonephritis treated in our hospital from August 2012 to December 2013 were randomly divided into treatment group (n = 43) and control group (n = 43). Patients in the control group were given routine treatment on admission, Such as salt restriction, control of food protein intake, diuretic and other basic treatment; treatment group in the control group on the basis of treatment given alprostadil 10μg intravenous injection, once daily + telmisartan 80mg orally, once daily, 14d 1 course of treatment. After 14 days of treatment, the changes of serum creatinine (Scr), 24-h urinary proteinuria (24h upro) and blood urea nitrogen (BUN) were compared between the two groups before and after treatment, and the clinical effects were compared between the two groups. Results The Scr, 24h Upro and BUN decreased significantly after treatment for 14 days in both groups, and decreased more significantly in the treatment group than that in the control group after treatment (P <0.05). After 28 days of treatment, the total effective rate in the treatment group was 95.35% Which was significantly higher than that of the control group (72.09%), the difference was statistically significant (P <0.05). Conclusion The combination of alprostadil and telmisartan in the treatment of chronic glomerulonephritis proteinuria clinical effect is significant, fewer adverse reactions, it is worth promoting the clinical application.